Journal
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
Volume 30, Issue 3, Pages 323-330Publisher
WROCLAW MEDICAL UNIV
DOI: 10.17219/acem/126288
Keywords
breast cancer; serum cysteine peptidase-like activity; chicken egg white cystatin; E-64 proteinase inhibitor
Categories
Ask authors/readers for more resources
The study evaluated the effects of specific inhibitors on autogenic cysteine peptidases in the sera of breast cancer patients, finding inhibitory effects in some samples but no correlation with the health indicators of the patients.
Background. The activity of autogenic proteolytic enzymes is regulated in vivo by autogenic inhibitors. They play important roles in maintaining a balance in many processes in the human body. In pathological conditions, enzymes are overexpressed and the balance is disturbed. Such uncontrolled changes may lead to the development of local or systemic cancer. Objectives. To evaluate the effects of specific inhibitors, i.e., chicken egg white cystatin (CEWC) and proteinase inhibitor (E-64) on autogenic cysteine peptidases (CPs) in the sera of patients reporting for subsequent stages of treatment after being diagnosed with breast cancer. Cysteine peptidases play a vital role in the basic processes that are associated with cancer progression. Materials and methods. We selected serum samples from 108 patients with a diagnosis of breast cancer (stages IIA-IIIA) who had received no previous treatment. The blood samples were centrifuged, and the resulting serum was placed in liquid nitrogen and stored at -80 degrees C. The biochemical tests were performed at the laboratory of the Department of Physical Chemistry and Microbiology. Results. For CEWC, we found an inhibitory effect in 37 out of 108 samples; for E-64, 14 out of 22 samples displayed an inhibitory effect. In the remaining blood samples, these inhibitors caused an increase in fluorescence. In a parallel test, we added pure cathepsin B to 9 serum samples, and then used CEWC to inhibit the activity of autogenic CPs. Chicken egg white cystatin completely inhibited the cathepsin B that was added to the serum without changing its effect on the autogenic CPs. Conclusions. The results suggest that there may be a potential difference between the commercially available cathepsin B and its autogenic analogues found in the serum of cancer patients. The increase in fluorescence induced in the reaction between the inhibitors and autogenic CPs is still unexplained. There was no relationship between the observed inhibition/activation of CPs and any of the available indicators of the health of the patients examined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available